AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00447473
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
Trial: NCT00447473
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
Trial: NCT00447473
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
Trial: NCT02270723
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Lactated Ringer during major surgery
Trial: NCT01151761
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2, IV
Trial: NCT01151761
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2, IV
Trial: NCT01151761
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 2, based on Calvert formula, IV
Trial: NCT02333890
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
Trial: NCT02559414
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02559414
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00083187
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00083187
Drug: laromustine
RxNorm normalized name: Laromustine
DrugBank: Laromustine (DB05817)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01131741
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group receives 3 mL of saline IV during operation.
Trial: NCT00265265
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00504140
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
Trial: NCT00504140
Drug: Interferon Alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
Trial: NCT00403780
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Trial: NCT03873506
Drug: transplantation of hUC-MSCs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
Trial: NCT04247126
Drug: SY-5609
RxNorm normalized name: SY-5609
DrugBank: SY-5609 (DB17099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral CDK7 Inhibitor
Trial: NCT04247126
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estrogen receptor antagonist
Trial: NCT04247126
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nucleoside metabolic inhibitor
Trial: NCT04247126
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taxane-type chemotherapy
Trial: NCT02311569
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
Trial: NCT04142151
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin produced by Bayer Co., Ltd.
Trial: NCT04142151
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel produced by Shenzhen Salubris Co., Ltd.
Trial: NCT04732104
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
Trial: NCT04732104
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
Trial: NCT00913393
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
Trial: NCT00913393
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
Trial: NCT03037541
Drug: Carac Cream
RxNorm normalized name: fluorouracil Topical Cream [Carac]
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carac Cream will be used once daily for seven consecutive days
Trial: NCT01922375
Drug: Naftopidil
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT00102713
Drug: Divalproex Sodium (Depakote Sprinkle Capsules)
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00306644
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT00003358
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003358
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02603445
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00531583
Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PBSCT
Trial: NCT01685983
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
Trial: NCT03308149
Drug: infiltration with triamcinolone and bupivacaine
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: facet joint infiltration
Trial: NCT00605267
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg once daily oral dose
Trial: NCT00605267
Drug: Anastrazole (Arimidex)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg once daily oral dose
Trial: NCT00605267
Drug: Goserelin acetate (Zoladex)
RxNorm normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6mg/month depot injection
Trial: NCT01330654
Drug: metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
Trial: NCT01443130
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
Trial: NCT01443130
Drug: Sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
Trial: NCT03278431
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) from Janssen, donated by the World Health Organization
Trial: NCT03278431
Drug: Pyrantel Pamoate
RxNorm normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
Trial: NCT03278431
Drug: Oxantel Pamoate
RxNorm normalized name: OXANTEL PAMOATE
DrugBank: Oxantel (DB13670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel
Trial: NCT03278431
Drug: Mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
Trial: NCT04149574
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified Dose on Specified Days
Trial: NCT00582738
Drug: CsA-TAC (standard Treatment)
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
Trial: NCT00582738
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hepatitis C recurrence after orthotopic liver transplantation (OLT)
Trial: NCT00364533
Drug: Tapentadol IR (CG5503)
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Dose 50, 75, \& 100 mg BID for 3 days
Trial: NCT00364533
Drug: Oxycodone HCL IR
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed Dose 10 mg BID for 3 days
Trial: NCT00364533
Drug: Tapentadol IR (CG5503)
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
Trial: NCT01473095
Drug: ARQ 092
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Trial: NCT00239954
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02749383
Drug: PAC-14028 cream 0.3%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02749383
Drug: PAC-14028 cream 1.0%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02749383
Drug: PAC-14028 cream vehicle
RxNorm normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT00321997
Drug: Pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01394887
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 mg of metformin twice daily over 12 weeks
Trial: NCT01480011
Drug: lactobacillus CD2 lozenges
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
Trial: NCT03123614
Drug: Loteprednol Etabonate 0.5% Oph Gel
RxNorm normalized name: LOTEPREDNOL ETABONATE 0.5% OPH GEL
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04591743
Drug: nicotine treatment
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
Trial: NCT00237380
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Trial: NCT03378648
Drug: umeclidinium bromide and vilanterol trifenatate
RxNorm normalized name: Vilanterol Trifenatate
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 3 Single dose
Trial: NCT05462808
Drug: High viscosity glass ionomer cement
RxNorm normalized name: Mineral Oil (high Viscosity)
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High viscosity glass ionomer cement
Trial: NCT00944463
Drug: Gemcitabine+Placebo
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine plus Placebo
Trial: NCT03931915
Drug: TAK-385
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
Trial: NCT03931915
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
Trial: NCT02184429
Drug: PF-06669571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
Trial: NCT02273713
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
Trial: NCT03926962
Drug: WCK 4873
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
Trial: NCT04710914
Drug: Prolonged sedation with isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam
Trial: NCT04710914
Drug: Prolonged sedation with midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam
Trial: NCT01703065
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally once a day
Trial: NCT01439126
Drug: clonidine hydrochloride
RxNorm normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
Trial: NCT01046240
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetron 3 mg administered SC or IV
Trial: NCT01290900
Drug: Ceftaroline
RxNorm normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Solution
Trial: NCT01290900
Drug: Ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Solution
Trial: NCT01290900
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet (1)
Trial: NCT04254874
Drug: Abidol hydrochloride
RxNorm normalized name: Acidol
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2g once, 3 times a day,two weeks
Trial: NCT04254874
Drug: Abidol Hydrochloride combined with Interferon atomization
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
Trial: NCT04129710
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.